MARKET

KROS

KROS

Keros Therapeutics, Inc.
NASDAQ
11.10
-0.07
-0.63%
Opening 15:31 09/11 EDT
OPEN
11.25
PREV CLOSE
11.17
HIGH
11.34
LOW
11.03
VOLUME
75.70K
TURNOVER
--
52 WEEK HIGH
22.55
52 WEEK LOW
9.69
MARKET CAP
220.08M
P/E (TTM)
-2.9976
1D
5D
1M
3M
1Y
5Y
1D
Keros Therapeutics Files Prospectus For Offering $350M Mixed Shelf; May Offer $100M Common Shares Under Sales Agreement With Leering Partners
Benzinga · 23h ago
Keros Therapeutics files $350M mixed securities shelf
TipRanks · 23h ago
Keros Therapeutics Authorises $ 5 Mln Share Buyback Following Elritercept Milestone; Stock Up
NASDAQ · 2d ago
Keros Therapeutics Launches $5M Share Buyback Following Development Milestone Payment
Dow Jones · 2d ago
Keros Therapeutics launches $5M share buyback after $20M milestone
Seeking Alpha · 2d ago
Keros Therapeutics announces $5M share repurchase program after Takeda payment
TipRanks · 2d ago
Keros Therapeutics Reveals $5M Share Repurchase Authorization
Benzinga · 2d ago
*Keros Therapeutics Announces $5M Shr Repurchase Authorization >KROS
Dow Jones · 2d ago
More
About KROS
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Webull offers Keros Therapeutics Inc stock information, including NASDAQ: KROS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KROS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KROS stock methods without spending real money on the virtual paper trading platform.